Cao, Xuanqi
Dai, Haiping
Cui, Qingya
Li, Zheng
Shen, Wenhong
Pan, Jinlan
Shen, Hongjie
Ma, Qinfen
Li, Mengyun
Chen, Sifan
Chen, Juncheng
Zhu, Xiaming
Meng, Huimin
Yang, Lin
Wu, Depei
Tang, Xiaowen
Clinical trials referenced in this document:
Documents that mention this clinical trial
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
https://doi.org/10.1186/s40164-022-00318-6
Funding for this research was provided by:
The Priority Academic Program Development of Jiangsu Higher Education Institutions
National Key Research and Development Program of China (2019YFC0840604)
Jiangsu Provincial Key Medical Center (YXZXA2016002)
National Natural Science Foundation of China (82020108003, 81730003, 81873443, 82070162, 81900175, 81400155, 81700139)
Major Natural Science Research Projects in institutions of higher education of Jiangsu Province (19KJA210002)
The Key Science Research Project of Jiangsu Commission of Health (K2019022)
Translational Research Grant of NCRCH (2020ZKZC04)
Natural Science Foundation of Jiangsu Province (BK20190181, BK20201169, BK20170360)
The Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province (BE2018652)
Article History
Received: 27 June 2022
Accepted: 11 September 2022
First Online: 29 September 2022
Declarations
:
: This clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.
: Not applicable.
: The authors declare that they have no competing interests.